Literature DB >> 10413651

Common variable immunodeficiency: clinical and immunological features of 248 patients.

C Cunningham-Rundles1, C Bodian.   

Abstract

Common variable immunodeficiency (CVI) is a primary immunodeficiency disease characterized by reduced serum immunoglobulins and heterogeneous clinical features. In these studies we describe the clinical and immunological status of 248 consecutively referred CVI patients of age range 3-79 years who have been followed for a period of 1-25 years. The median age at the time of onset of symptoms was 23 years for males and 28 years for females; the mean age at which the diagnosis of CVI was made was 29 years for males and 33 years for females. Forty percent of patients had impaired T cell proliferation to one or more mitogens; lymphocyte transformation to mitogens was directly related to the level of the serum IgG. Females at all ages had higher levels of serum IgM than males. Survival 20 years after diagnosis of CVI was 64% for males and 67% for females, compared to the expected 92% population survival for males and 94% for females. Parameters associated with mortality in this period were lower levels of serum IgG, poorer T cell responses to phytohemagglutinin, and, particularly, a lower percentage of peripheral B cells (P < 0.006). Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413651     DOI: 10.1006/clim.1999.4725

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  416 in total

Review 1.  X-linked lymphoproliferative syndrome.

Authors:  D L Nelson; C Terhorst
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 2.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).

Authors:  L Hammarström; I Vorechovsky; D Webster
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

3.  Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation.

Authors:  M Di Renzo; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

4.  Gastrointestinal Manifestations of Non-AIDS Immunodeficiency.

Authors:  Robert P. McCabe
Journal:  Curr Treat Options Gastroenterol       Date:  2002-02

5.  Enhanced T cell apoptosis in common variable immunodeficiency: negative role of the fas/fasligand system and of the Bcl-2 family proteins and possible role of TNF-RS.

Authors:  M Di Renzo; D Serrano; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

6.  Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype.

Authors:  Hye Sun Kuehn; Julie E Niemela; Karthik Sreedhara; Jennifer L Stoddard; Jennifer Grossman; Christian A Wysocki; M Teresa de la Morena; Mary Garofalo; Jingga Inlora; Michael P Snyder; David B Lewis; Constantine A Stratakis; Thomas A Fleisher; Sergio D Rosenzweig
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

7.  T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections.

Authors:  E A L Bateman; L Ayers; R Sadler; M Lucas; C Roberts; A Woods; K Packwood; J Burden; D Harrison; N Kaenzig; M Lee; H M Chapel; B L Ferry
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

Review 8.  Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders.

Authors:  Ramona Goyal; Ariel C Bulua; Nikolay P Nikolov; Pamela L Schwartzberg; Richard M Siegel
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 9.  Diarrhoea due to small bowel diseases.

Authors:  Joseph A Murray; Alberto Rubio-Tapia
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-10       Impact factor: 3.043

Review 10.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.